恩度持续静脉泵注联合TN方案治疗晚期食管癌的临床研究

发布时间：2018-05-12 23:04

本文选题：恩度 + 晚期食管癌　；参考：《青海大学》2017年硕士论文

【摘要】：目的:探讨恩度持续静脉泵注联合TN(紫杉醇+奈达铂)方案治疗晚期食管癌的临床有效性和安全性,从而对临床给药方案提供一定的指导作用。方法:收集自2015年4月至2016年10月就诊于我科的初治晚期食管癌患者60例,随机将入组患者分为实验组(30例)、对照组(30例)两组。实验组予以恩度联合TN方案,对照组仅给予TN方案,记录所有入组患者的基线水平,包括血液系统、CT、胃镜、浅表彩超等信息数据、每2周期治疗后再次复查,对所记录的结果资料进行统计学分析。结果:1.近期疗效两组60例患者均完成2-6个周期化疗,均可评价近期疗效。两组患者完全缓解(CR)均为0例;部分缓解(PR)19例,试验组为11例、对照组为8例;稳定(SD)21例,试验组为13例、对照组为8例;进展(PD)20例,试验组为6例、对照组为14例;有效率(CR+PR)实验组为36.7%、对照组为26.7%,疾病控制率(CR+PR+SD)试验组为80%、对照组为53.3%;有效率比较,两组不存在显著性差异,P0.05;疾病控制率比较,两组差异具有统计学意义,P0.05;2.安全性评价两组患者化疗毒副反应为血液毒性、胃肠反应、肝肾功损害、心电图异常等方面。毒副反应均为I-II度为主,两组毒副反应程比较,差异均无统计学意义,P0.05。3.中位无进展生存期(progression-free survival PFS)实验组为5.9月,对照组为5.4月;Log-rank检验示P0.05;两组差异有统计学意义;结论:恩度持续静脉泵注联合TN方案治疗晚期食管癌,与对照组比较,未能提高患者有效率,但可以提高疾病控制率,能够有效控制和延缓其病情发展;两组毒副反应均以I-II度为主,与对照组比较,增加恩度,并未使原方案毒性反应加重,可耐受;实验组PFS较对照组延长,恩度持续静脉泵注联合TN方案能延长晚期食管癌患者PFS;可进一步临床观察研究。
[Abstract]:Objective: to investigate the clinical efficacy and safety of continuous intravenous infusion of Endol combined with TNT in the treatment of advanced esophageal carcinoma. Methods: from April 2015 to October 2016, 60 patients with advanced esophageal cancer were randomly divided into experimental group (n = 30) and control group (n = 30). The experimental group was given Endor combined with TN scheme, the control group was only given TN regimen, the baseline level of all the patients in the group was recorded, including blood system CTS, gastroscopy, superficial color ultrasound and other information data, and re-examined every 2 cycles after treatment. The recorded results were statistically analyzed. The result is 1: 1. Two-six cycles of chemotherapy were completed in both groups. In both groups, there were 0 cases of complete remission, 19 cases of partial remission of PRI, 11 cases of experimental group and 8 cases of control group, 21 cases of stable SDN, 13 cases of experimental group and 8 cases of control group, 20 cases of PDD, 6 cases of experimental group and 14 cases of control group. The effective rate of CR was 36.7 in the experimental group, 26.7in the control group, 80 in the control group and 53.3 in the control group. There was no significant difference in the effective rate between the two groups (P0.05), and the difference between the two groups was statistically significant (P 0.052). Safety evaluation: side effects of chemotherapy in two groups were blood toxicity, gastrointestinal reaction, liver and kidney damage, abnormal ECG and so on. The side effects were mainly I-II degree, and there was no significant difference between the two groups (P 0.05.3). The median progression-free survival PFSs were 5.9 months in the experimental group and 5.5 months in the control group. The difference between the two groups was statistically significant. Conclusion: the treatment of advanced esophageal carcinoma with continuous intravenous infusion of Endor plus TN regimen was compared with that of the control group. Failure to improve the effective rate of the patients, but can improve the disease control rate, can effectively control and delay the development of their condition; the two groups of toxic side effects are mainly I-II degree, compared with the control group, increase the degree of grace, did not make the original program toxic reaction aggravated, The PFS in the experimental group was longer than that in the control group, and combined with TN regimen could prolong the PFS in the patients with advanced esophageal cancer.
【学位授予单位】：青海大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735.1

【相似文献】